The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Sæmundur RögnvaldssonDuring the 12th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-12), the Lymphoma Hub was pleased to speak to Sæmundur Rögnvaldsson, University of Iceland, Reykjavik, IS. We asked about the iStopMM study and the implications of these data for both patients with multiple myeloma (MM) and those with Waldenstrom's macroglobulinemia (WM).
Lym + MM hub Sæmundur Rögnvaldsson iSTOPMM in MM and WM
In this interview, Rögnvaldsson discusses his role in the iStopMM (NCT03327597) study, which screens for monoclonal gammopathies (MGUS) to detect early MM and WM. Rögnvaldsson highlights the key findings, including the potential for early diagnosis to reduce disease severity and hospitalizations. Rögnvaldsson also covers the study's long-term goals, including refining follow-up, developing predictive models for progression, and understanding the biological processes behind benign versus malignant conditions. He concludes with a look at how these data could help improve outcomes in both MM and WM through optimized treatment and disease management.
Your opinion matters
As a result of this content, I commit to reviewing the latest data from clinical trials of novel therapies for the treatment of Waldenstrom’s macroglobulinemia.
This educational resource was independently supported by BeiGene. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content